723 results about "Target peptide" patented technology

The invention provides a preparation method of mitochondria-targeted antioxidant hybrid vesicles. The preparation method comprises the following steps: S1, preparing and separating adipose-derived stem cell nano-vesicles; s2, preparing a liposome loaded with dihydromyricetin and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-triphenylphosphine targeting peptide by an ethanol injection method; and S3, preparing the hybrid nano vesicles loaded with the dihydromyricetin and the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-triphenylphosphine targeting peptide. The invention also provides the hybrid vesicles prepared by the method and application of the hybrid vesicles in preparation of refractory diabetes wound treatment drugs. The lipidosome and the adipose-derived stem cell nano-vesicles are hybridized to prepare the hybridized vesicles capable of targeting mitochondria and resisting oxidation, the hybridized vesicles are applied to wound treatment for the first time, the problem of oxidative stress of diabetic wounds is solved, wound healing is accelerated, and a new strategy is provided for optimizing mitochondrial function defects and oxidative stress of the diabetic wounds.

The invention belongs to the technical field of medicine, and discloses an active targeting atherosclerotic plaque liposome and application thereof in diagnosis, a carrier material for forming the liposome comprises targeting peptide R8 modified methoxy polyethylene glycol phospholipid (R8-DSPE-PEG), polypropylene sulfide-polyethylene glycol (PPS-PEG) and cholesterol (CH), and the targeting peptide R8 modified methoxy polyethylene glycol phospholipid (R8-DSPE-PEG), the polypropylene sulfide-polyethylene glycol (PPS-PEG) and the cholesterol (CH) are combined to form the active targeting atherosclerotic plaque liposome. The sequence of the targeting peptide R8 is Asp-Ser-Ser-Ser-Gln-Cys-His-Arg, and the sequence of the targeting peptide R8 is Asp-Ser-Ser-Gln-Cys-His- The liposome provided by the invention can improve the enrichment concentration of a fluorescent dye or a drug in local lesion, and has the advantages of low toxicity and high efficiency, and the obtained targeted liposome has a good effect on diagnosis of atherosclerosis.

The invention discloses a PEI and targeting peptide modified magnetic nano-carrier and a preparation method and application thereof. The nano-carrier is regular in morphology and uniform in particle size and has good crystallinity and magnetic performance. E5 polypeptide and RGD cyclic peptide on the surface of the nano-carrier are respectively combined with CXCR4 protein and integrin on the surface of a tumor cell, and the nano-carrier and CXCR4 are internalized into lysosome through an integrin-mediated way, so that the target protein CXCR4 is degraded. The PEI in the nano-carrier can load and deliver siRNA into tumor cells to silence the expression of CXCR4 mRNA (messenger Ribonucleic Acid). Through nucleic acid delivery and a protein targeted degradation strategy, the CXCR4 level of tumor cells is jointly reduced, the migration ability of the tumor cells is inhibited, and meanwhile, the anti-tumor effect of M1 type polarization of macrophages is activated.

The invention discloses an enzyme response type KRAS targeted protein degradation chimera as well as a preparation method and application thereof, and belongs to the technical field of tumor targeted therapy. The enzyme response type KRAS targeted protein degradation chimera disclosed by the invention is obtained by covalently linking three parts, namely a KRAS targeted protein degradation chimera, an enzyme response type amino acid sequence and a cell penetrating peptide amino acid sequence, wherein the KRAS targeted protein degradation chimera is obtained by linking a KRAS targeted peptide and a VHL E3 ligase ligand through succinic acid. The enzyme response type KRAS targeted protein degradation chimera releases the KRAS targeted protein degradation chimera under the action of ATG4 enzyme shearing, and shows a relatively strong lung cancer resisting effect in vitro and in vivo. The invention has significant advantages in the aspect of antitumor drugs, and opens up a new field for the development of targeted protein degradation chimera drugs. Enzyme response type KRAS targeted protein degradation chimera molecular structural formula as follows: # imgabs0 #

The invention provides a preparation method of a Janus material for simultaneous screening of protein phosphorylation and palmitoylation modification, and belongs to the technical field of magnetic material synthesis. The method comprises the following steps: firstly, preparing MCeO2; the preparation method comprises the following steps: mixing MCeO2, hexadecyl trimethyl ammonium bromide and ammonia water to obtain a mixed solution, adding 1, 2-bis (triethoxysilane) ethane into the mixed solution for reaction to obtain a product, and dispersing the product into an NH4NO3 solution for reflux reaction to obtain Janus MCP; the preparation method comprises the following steps: reacting Janus MCP with a silane coupling agent, dissolving aminated Janus MCP and 4-ethylene sulfonyl benzoic acid in a buffer solution containing EDC and NHS, and reacting to obtain the Janus material. The preparation method is reliable, the material performance is stable, and the enrichment efficiency of the magnetic Janus on target peptide fragments (phosphorylated peptide fragments and palmitoylated peptide fragments) is remarkably improved.

The invention provides a preparation method of tiall peptide, and belongs to the technical field of polypeptide synthesis, according to the preparation method, a small amount of lysis solution is adopted for lysis, a small amount of poor solution composed of methyl tert-butyl ether and n-heptane with the volume ratio of 1-2: 1 is used for crude peptide precipitation, precipitated particles are uniform, large and not prone to caking, the crude peptide impurity level is lower, and the purity of the crude peptide is higher. The method has the advantages that the method is simple in process and easy in subsequent purification step, the amount of generated waste liquid is small, the activating agent 7-(1H-pyrrolo [2, 3-b] pyridine-1-yl)-1H-benzo [d] [1, 2, 3] triazole-1-alcohol is used for activating amino acid, the coupling reaction degree is high, and the target peptide yield is high. The preparation method of the tilpotide has the advantages of being simple, economical, capable of achieving mass production, low in impurity content, high in purification yield, high in yield and the like.

Provided herein are compositions including brain, brain microvascular endothelial cell-targeting peptides and / or blood-brain barrier crossing (BBB) tissue-targeting peptides linked thereto or inserted in a targeting protein of a recombinant vector having at least one exogenous peptide comprising Xn – n-mer – Xm. Compositions providing such conjugates, targeting peptides, or recombinant vectors having an engineered capsid or envelope protein are provided as are uses thereof.

The present disclosure relates to targeting moieties such as peptides that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and / or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

The invention belongs to the technical field of biomedical materials, and particularly relates to a photothermal nano-drug containing a guanidyl structure as well as a preparation method and application of the photothermal nano-drug, and the photothermal nano-drug is CA-COFBT-TG (at) TS obtained by taking COFBT-TG containing guanidyl as a carrier, loading a photothermal agent TS and then modifying a fibrin targeting peptide CA on the surface. The photo-thermal nano-drug is a covalent organic framework material platform, can be enriched at a thrombus part, has excellent photo-thermal conversion performance, can effectively remove thrombus at a focus part, and can improve neuronal death after cerebral arterial thrombosis by inhibiting ferroptosis.

Preparation for an siRNA and drug co-delivery system for efficiently targeting glioma initiating cells, and a use; D VAP targeting peptide modification is performed on exosomes by utilizing a click chemistry method, siRNA and mitoxantrone are loaded into the exosomes, and construction is performed to obtain a target-modified drug carrier exosome DVAP-Exo / siRNA / MIT. The target-modified exosome co-carries chemotherapeutic mitoxantrone, which has a strong killing effect on glioma initiating cells and can trigger immunogenic cell death, and a small interfering nucleic acid (siNotch 1), which is capable of reducing glioma initiating cell stemness; targeted tracking and killing of residual glioma initiating cells and tumor cells are achieved, and a new avenue is provided for glioblastoma treatment.

The invention discloses a TCR (T cell receptor)-like monoclonal antibody for treating NPM1 type A mutant acute leukemia, which is a recombinant protein pNPM1-HLA protein expressed by SEQ ID NO1 or SEQ ID NO2, the recombinant protein is combined with a monoclonal antibody of pNPM1-HLA-A2, the monoclonal antibody can specifically recognize the combination of the pNPM1-HLA-A2 protein on the surface of a tumor cell, the combination with a non-target peptide / HLA-A2 protein is low, and the monoclonal antibody can be used for treating NPM1 type A mutant acute leukemia. The specific recognition on the tumor cells is realized. The monoclonal antibody provided by the invention has the following advantages: (1) the monoclonal antibody 2E2 has high affinity with a target protein, and Biacore affinity detection KD (M) is 1.58 e <-7 >; and (2) the antibody can be combined with a tumor cell line for expressing pNPM1-HLA-A2. And (3) the modified antibody has an obvious killing effect on tumor cells in vitro and in vivo.

This invention belongs to the field of biomedical technology and discloses a method for targeting GABA. A The receptor-dependent cyclic peptide analgesic DZ2 has the following amino acid sequence: Cys-Asn-Thr-Glu-Arg-Pro-Gly-Met-Leu-Asp-Phe-Lys-Gly-Lys-Ala-Lys-Trp-Asp-Ala-Trp-Cys, where the N-terminal Cys and C-terminal Cys are cyclically linked by a disulfide bond, and the molecular weight is 2454.81 g / mol. This cyclic peptide can be obtained through classic Fmoc-solid-phase synthesis, using GABA... A Receptor-targeting drugs play an important role in drug development. The compounds provided in this invention can activate GABA. A The receptor generates a GABA-like inward current. Furthermore, DZ2 exhibits excellent analgesic effects in a mouse pain model, providing a potential alternative for GABA-based analgesics. A This provides new ideas and theoretical basis for the development of receptor-based analgesics.

The present disclosure relates to targeting moieties such as peptides that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and / or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

The invention belongs to the technical field of biological medicines, and particularly relates to a wheat peptide with antioxidant stress activity and a preparation method and application thereof. The invention provides a wheat peptide with antioxidant stress activity. The amino acid sequence of the wheat peptide is as shown in SEQ ID NO: 1. The invention discloses a wheat peptide FGWPGPK for protecting oxidative stress nerve cells as well as a screening method and application of the wheat peptide FGWPGPK. A target peptide fragment is identified from wheat germs through enzymolysis and multi-dimensional screening strategies, and it is proved that the target peptide fragment can significantly improve the survival rate of PC-12 cells damaged by H2O2 (72.88%) and reduce the ROS level (125.54%). The peptide fragment has strong antioxidant activity and nerve targeting property, and is suitable for preventing and treating neurodegenerative diseases such as Alzheimer's disease.

The present invention belongs to the field of medical technology, and discloses a liposome that actively targets atherosclerotic plaques and its application in diagnosis. The carrier material forming the liposome includes a targeting peptide R8 modified with methoxy polyethylene glycol phospholipid (R8-DSPE-PEG), polysulfide propylene-polyethylene glycol (PPS-PEG) and cholesterol (CH), and the sequence of the targeting peptide R8 is Asp-Ser-Ser-Ser-Gln-Cys-His-Arg. The liposome of the present invention can increase the enrichment concentration of fluorescent dyes or drugs in the local lesion, has the advantages of low toxicity and high efficiency, and the obtained targeted liposome has a good effect on the diagnosis of atherosclerosis.

The invention provides a preparation method and application of a turmeric extracellular vesicle targeted drug delivery system with an anti-colon cancer effect. The engineering system of modifying CELNs and loading DOX by the TCP-1 colon cancer targeting peptide is constructed by extracting curcuma longa extracellular vesicles (CELNs). The system of loading adriamycin through targeted modified turmeric extracellular vesicles has better anti-tumor activity and tumor targeting property, and HE staining and serum detection results show that the system has no significant influence on important tissues, visceral organs and liver functions of mice. And the biological safety is improved while a better treatment effect is achieved.

The present disclosure relates to targeting moieties such as peptides that can bind to B7-H3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and / or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

The invention belongs to the field of tumor drug research, and particularly relates to a cell vesicle co-delivery system, an anti-tumor drug and application. The cell vesicle-like co-delivery system is constructed according to the following steps: co-transfecting a recombinant expression vector of tumor targeting protein or targeting peptide and a recombinant plasmid of circRNA of effector molecules related to pyroptosis to a tool cell, and collecting to obtain the cell vesicle-like co-delivery system, a recombinant expression vector of the tumor targeting protein or the targeting peptide contains a DNA sequence for coding MCP protein, and a recombinant plasmid of circRNA of an effector molecule related to pyroptosis contains a DNA sequence for coding MS2 protein. According to the cell vesicle co-delivery system provided by the invention, tumor cell death is directly induced by delivering the cell death related effector molecule RNA through the cell vesicles, the killing efficiency is high, the side effect is relatively small, and the problems of mass production and drug loading can be solved.

The invention discloses a multifunctional nano delivery system based on targeted ferritin as well as a preparation method and application of the multifunctional nano delivery system. According to the system, traditional Chinese medicine active ingredients, namely neogambogic acid GNA, a photosensitizer Ce6 and ferritin targeting peptide HKN15 are integrated through a self-assembly technology, a synergistic treatment system integrating photodynamic therapy PDT and ferroptosis induction is constructed, and the treatment effect on non-small cell lung cancer NSCLC can be remarkably enhanced. According to the nano delivery system, precise targeting of a tumor site is achieved through the ferritin targeting peptide HKN15, and a double anti-tumor mechanism is formed by utilizing the photodynamic effect of the photosensitizer Ce6 and the ferroptosis induction effect of GNA. The preparation process is based on a molecular self-assembly principle, and has the advantages of high tumor accumulation efficiency, low system toxicity, remarkable tumor inhibition effect and the like, and an innovative solution is provided for precise treatment of the non-small cell lung cancer.

The invention discloses a TREM-1 inhibitory peptide nano-particle which is prepared by the following steps: by taking a dendritic polymer PAMAM as a carrier, coupling a TREM-1 inhibitory peptide with amino groups on the carrier by utilizing the characteristic of polyamino groups on the surface of the PAMAM, and coupling a brain-targeted peptide with the other part of amino groups on the carrier through MAL-PEG2000-NHS, so as to obtain the TREM-1 inhibitory peptide nano-particle. And modifying the residual amino groups on the carrier with PEG (Polyethylene Glycol) to obtain the nano-particles. The nanoparticles can relieve encephaledema, neuroinflammation injury and blood brain barrier damage caused by traumatic craniocerebral injury, improve cognitive impairment and long-term prognosis after trauma, and have a very high curative effect on clinical treatment of craniocerebral injury.

The present disclosure relates to targeting moieties such as peptides and antibodies that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and / or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

The invention discloses a tumor targeting reagent and application thereof in tumor diagnosis. The targeting reagent has strong affinity to tumors, strong specificity and no biotoxicity, is relatively stable in vivo, and can be used as a molecular probe to be applied to molecular imaging and / or treatment of various integrin alpha6 high-expression tumors; the targeting reagent provided by the invention comprises the tumor targeting peptide RWYDeA, and further comprises a radionuclide chelating agent, other connecting structures and a hydroxyl substitution structure, and the structure is beneficial to improving the tumor targeting property of the targeting reagent, prolonging the tumor binding time and achieving a better tumor diagnosis effect; the method can be used for preparing products for diagnosing / treating diseases related to high expression of integrin alpha6.

The present disclosure relates to targeting moieties such as peptides and antibodies that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and / or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

The invention discloses a broad-spectrum novel coronavirus-resistant double-target polypeptide and application thereof, and relates to the field of biological medicines. The polypeptide drug provided by the invention can more effectively and synergistically inhibit the infection process of the virus by simultaneously acting on two key targets of RBD and HR1 of the virus. On one hand, through targeting RBD, combination of viruses and host cells can be blocked, so that the phenomenon that the viruses are adsorbed on the surfaces of the host cells is blocked, and the adsorption process of the viruses is restrained; on the other hand, by targeting HR1, formation of virus 6-HB can be interfered, and the fusion process of a virus envelope and a host envelope is further inhibited. The polypeptide capable of simultaneously targeting the double targets RBD and HR1 of the novel coronavirus, particularly R1L25HR2, provided by the invention, can effectively inhibit SARS-CoV-2 and a mutant strain thereof, and has broad-spectrum activity for resisting the novel coronavirus.

The invention discloses an ROS-responsive prostate cancer targeting prodrug as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The prodrug is formed by covalently linking a prostate cancer targeting peptide SYEELR, a ROS (reactive oxygen species) response type ketal thiol (TK) connexon and an active molecule Devimistat. The preparation method comprises the following two steps: firstly, coupling Devimistat with a TK linker to obtain an intermediate Dev-TK, and then coupling the intermediate Dev-TK with an SYEELR peptide fragment to obtain a target product. The prodrug can specifically break and release Devimistat in a tumor high active oxygen microenvironment, and active targeting delivery is realized by virtue of the SYEELR peptide. The invention provides a novel prostatic cancer treatment strategy with accurate targeting, controllable release, enhanced curative effect and toxicity reduction potential.

The invention relates to the technical field of food processing, and particularly discloses soybean flavor peptide and a preparation method and application thereof. Aspergillus oryzae is selected as a leavening agent, a microbial endogenous enzyme generated by full fermentation of the aspergillus oryzae is utilized to cooperate with a compound enzyme preparation to perform combined action, abundant enzyme systems effectively perform enzymolysis on macromolecules such as protein, and related taste substances are provided for subsequent enzymolysis products; in the soybean flavor peptide prepared by enzyme hydrolysis and Maillard reaction, the contents of target peptide and target amino acid (umami peptide, umami amino acid and the like) are high; when the soybean flavor peptide is applied to the compound seasoning with the main function of increasing freshness, the freshness score can be increased by 0.5-2 times. In addition, on the basis of improving freshness, the taste richness of the food or the compound seasoning can be enhanced, and the aftertaste time is prolonged.

The invention provides a response liposome for treating traumatic brain injury by targeting a blood-brain barrier loaded drug and a preparation method of the response liposome, and belongs to the field of traumatic brain injury treatment.The response liposome is prepared by preparing TfR-T12 target peptide firstly, then preparing nano-particles with hydrophobic molecular drugs wrapped inside, and finally preparing the TfR-T12 target peptide with the hydrophobic molecular drugs wrapped inside. And finally, preparing the response liposome for treating traumatic brain injury by the targeted blood-brain barrier loaded medicine. According to the application, the TfR-T12 target peptide which is highly expressed in cerebral cortex microvessels and can help a nano-drug to pass through a blood brain barrier through endocytosis is prepared as a target spot, meanwhile, the liposome is subjected to polypeptide modification, and the self-assembly driving force of the nano-particles is improved through process control; the outer surface of the response lipidosome is a target peptide, and the response lipidosome is internally coated with a nano-drug; the liposome can repair the blood brain barrier after injury, improve the blood flow of the brain, improve the drainage of the colloidal lymphatic system, improve the motor and cognitive functions of mice after injury, and reduce the dosage of drugs and various possible side effects caused by the drug dosage.

The invention belongs to the field of gene therapy, and relates to a DNA (deoxyribonucleic acid) molecule for targeted degradation of target protein and application. The DNA molecule comprises at least one group of D-PROTAC units, each group of D-PROTAC units comprises at least one first DNA chain segment for coding a ubiquitin ligase targeting peptide and at least one second DNA chain segment for coding a target protein targeting peptide, and a third DNA chain segment for coding a connecting peptide is optionally arranged between the adjacent first DNA chain segment and second DNA chain segment. The gene therapy specific PROTAC molecular model is successfully constructed, the huge potential of a gene therapy method in the aspects of research, development and application of new PROTAC anticancer drugs is proved, the action mode of the PROTAC technology is innovated, and a new treatment application scene is expanded for gene therapy.

The invention provides a cyclodextrin-based nano anti-tumor medicine preparation as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: preparing a graphene quantum dot deposition gold nanocage modified by a silane coupling agent, carrying out a Schiff base reaction on the graphene quantum dot deposition gold nanocage and aldehyde substituted-beta-cyclodextrin to prepare a composite carrier, and coating a targeted peptide-drug compound through the reaction, thereby preparing the cyclodextrin-based nano anti-tumor drug preparation. According to the cyclodextrin-based nano anti-tumor medicine preparation prepared by the invention, the anti-tumor medicine effect is obviously improved, meanwhile, the medicine resistance of the medicine can be reversed, the damage to normal tissues is reduced, the use amount of the medicine is reduced, the side effect after the medicine is used is reduced, the compliance of a patient is improved, and meanwhile, the stability and biocompatibility of the medicine can be improved; wide application prospects are realized.

The invention provides a synthesis method of tilpotide, which comprises the following steps: dividing a target peptide chain into six fragments, and adopting bis (4-C18-C28 alkoxy phenyl) methylamine, 2, 4-bis (18-C28 alkoxy)-benzyl alcohol and NH2-Asp (OTAG)-OR1 as hydrophobic label carriers to assist synthesis. A side chain carboxyl group of aspartic acid is innovatively used as an anchoring position of a hydrophobic label, a new fragment connection route is designed, a full-protection tilpotide conjugate is synthesized through a multi-label synergistic effect, and finally a protecting group and a label are removed by using a TFA lysate. Compared with a solid-phase synthesis method, the method is carried out in a homogeneous reaction, the dosage of amino acid and the condensing agent is reduced to 1-1.2 times from 2-3 times, and the cost is remarkably reduced. Compared with an existing hydrophobic labeling method, the method has the advantages that multiple labels can be introduced to serve as protecting groups, the yield and purity of synthesis of medium-chain and long-chain polypeptides are improved, meanwhile, the problem of hydrophobicity attenuation caused by peptide chain extension is solved, and the green chemical process requirement is met.